Fulgent Genetics (FLGT) Equity Average (2016 - 2026)

Fulgent Genetics (FLGT) has 11 years of Equity Average data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Equity Average fell 4.25% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 4.25% YoY) and the FY2025 annual result came in at $1.1 billion, down 0.94% from the prior year.
• Equity Average slipped to $1.1 billion in Q1 2026 per FLGT's latest filing, from $1.1 billion in the prior quarter.
• The five-year high for Equity Average was $1.3 billion in Q2 2022, with the low at $1.1 billion in Q1 2026.
• Average Equity Average over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Equity Average jumped 80.81% in 2022 and slipped 10.98% in 2024.
• Fulgent Genetics' Equity Average stood at $1.3 billion in 2022, then fell by 6.12% to $1.2 billion in 2023, then slipped by 5.47% to $1.1 billion in 2024, then retreated by 1.38% to $1.1 billion in 2025, then decreased by 3.43% to $1.1 billion in 2026.
• Business Quant data shows FLGT's Equity Average at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.